Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response.

Autor:	Moody AS; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA.; Carolina Institute for Nanomedicine, Chapel Hill, NC 27599, USA.; Joint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill, NC 27599, USA., Dayton PA; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA.; Joint Department of Biomedical Engineering, University of North Carolina and North Carolina State University, Chapel Hill, NC 27599, USA., Zamboni WC; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA.; Carolina Institute for Nanomedicine, Chapel Hill, NC 27599, USA.
Jazyk:	angličtina
Zdroj:	Cancer drug resistance (Alhambra, Calif.) [Cancer Drug Resist] 2021; Vol. 4, pp. 382-413. Date of Electronic Publication: 2021 Jun 19.
DOI:	10.20517/cdr.2020.94
Abstrakt:	Standard small molecule and nanoparticulate chemotherapies are used for cancer treatment; however, their effectiveness remains highly variable. One reason for this variable response is hypothesized to be due to nonspecific drug distribution and heterogeneity of the tumor microenvironment, which affect tumor delivery of the agents. Nanoparticle drugs have many theoretical advantages, but due to variability in tumor microenvironment (TME) factors, the overall drug delivery to tumors and associated antitumor response are low. The nanotechnology field would greatly benefit from a thorough analysis of the TME factors that create these physiological barriers to tumor delivery and treatment in preclinical models and in patients. Thus, there is a need to develop methods that can be used to reveal the content of the TME, determine how these TME factors affect drug delivery, and modulate TME factors to increase the tumor delivery and efficacy of nanoparticles. In this review, we will discuss TME factors involved in drug delivery, and how biomedical imaging tools can be used to evaluate tumor barriers and predict drug delivery to tumors and antitumor response. Competing Interests: Conflicts of interest P.A.D. Declares inventorship on patents describing ultrasound imaging, contrast agents, and ultrasound therapeutics. He is a co-founder of SonoVol, Inc., and Triangle Biotechnology, Inc., companies which have licensed these patents.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu